1352610-22-0

Basic information

• Product Name: N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-3-vinylaniline sulfate
• Synonyms: N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-3-vinylaniline sulfate
• CAS NO: 1352610-22-0
• Molecular Weight: 505.557
• Mol File: 1352610-22-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-3-vinylaniline sulfate(CAS DataBase Reference)
• NIST Chemistry Reference: N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-3-vinylaniline sulfate(1352610-22-0)
• EPA Substance Registry System: N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-3-vinylaniline sulfate(1352610-22-0)

Safety Data

• Hazardous Substances Data: 1352610-22-0(Hazardous Substances Data)

Upstream product

• 614750-82-2 1-(6-methylpyridin-2-yl)-2-[1,2,4]triazolo-[1,5-a]pyridin-6-yl-ethanone 
• 356560-84-4 1-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-(6-methylpyridin-2-yl)ethane-1,2-dione 
• 1352609-09-6 N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-3-vinylaniline 
• 1352609-89-2 6-(2-(dimethoxymethyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridine 
• 1352609-91-6 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazole-2-carbaldehyde 
• 614750-85-5 diphenyl (6-methylpyridin-2-yl)(phenylamino)methylphosphonate 
• 1122-72-1 6-methyl-2-pyridinecarboxaldehyde 

Relevant articles and documents

2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors

This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.